Valuation dashboard for Jazz Pharmaceuticals plc (JAZZ) with P/E 15.50, P/B 3.10, EV/EBITDA 132.76 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymph...
Analysis Summary
Jazz Pharmaceuticals plc reported revenue of $4.27B in the most recent fiscal year, growing at a 5-year CAGR of 12.5%.
Trailing-twelve-month margins: gross margin 84.7%, operating margin 31.1%, net margin 20.4%.
At the current price of $236.04, JAZZ trades at a P/E of 15.50 and an ROE of -8.25%. Market capitalisation stands at $14.8B, placing it among large-cap names.
Balance sheet quality for JAZZ: current ratio of 1.9. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 15.50 |
| Price / Book | 3.10 |
| EV / EBITDA | 132.76 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $341.18 |
| vs Current Price | +44.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $14.9B | 15.50 | 3.10 | -8.2% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.8B | 27.79 | -56.6% | |
| AXSM | Axsome Therapeutics, Inc. | $9.4B | 109.35 | -255.6% | |
| ABVX | Abivax S.A. | $6.8B | 18.05 | -85.9% | |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | 31.21 | 89.76 | 180.6% |
| CYTK | Cytokinetics, Incorporated | $8.2B | 164.0% | ||
| NUVL | Nuvalent, Inc. | $9.1B | 8.30 | -42.8% | |
| CAI | Caris Life Sciences, Inc. | $8.6B | 76.10 | 13.53 | 18.8% |
Price
| Price | $236.04 |
| Market Cap | $14.8B |
| Exchange | NASDAQ |
| Country | IE |
Profitability
| Return on Equity | -8.25% |
| Return on Invested Capital | 1.22% |
| Return on Assets | -3.05% |
| Gross Margin | 84.67% |
| Operating Margin | 31.05% |
| Net Margin | 20.45% |
Related companies: ABVX · AXSM · CAI · CYTK · HALO · MDGL · MRUS
Explore sector: Healthcare · Biotechnology
More sections of JAZZ: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks